Interestingly, in the dataset reported by Raab and Co. [95], BCL-xL expression increased significantly on time dependent in MM.1S myeloma cell line after treatment with enzaustarin, a protein kinase C inhibitor with evidence of promoting apoptosis and inhibiting proliferation [70,95] (Figure 13C). Here, BCL2L1 is linked to plasma cell myeloma.